BNTC

Benitec Biopharma Inc.

Healthcare
Biotechnology
$302M market cap

Forecast run · Oct 29, 2026Upside rank 815 of 3,186

Model Signal

ForecastQ Daily Probabilities

38.0%

54.3%

32.0%

Analyst Consensus

Recommendation2.13/5 Buy

Last price$8.65

Price target$18.67

Implied move+115.8%

Analysts8

ForecastQ Portfolios

BNTC is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.